Novartis India Pays ₹1,250 Cr for Pfizer's Minipress Brands, Six Weeks After ChrysCapital Took Control

On September 7, Novartis India's board approved — and the company signed and closed, the same day — the purchase of the trademarks 'Minipress' and 'Minipres' registered in India, along with certain related intellectual property rights, from Pfizer Inc. USA and Pfizer Products Inc. USA. The consideration: ₹12,50,00,10,000 — one thousand two hundred fifty crores and ten thousand rupees, i.e. ₹1,250.0 Cr. Against the company's own market value of roughly ₹4,096 Cr (2.47 Cr shares at the ₹1,658.95 close), that is a commitment of about 31% of market cap for one acquired brand — an unusually large single move for a company of this size.

The filing reached the exchange at 11:24 IST, during Monday's session; the stock closed at ₹1,658.95, up 1.2% on the day, on volume of 1,41,247 shares — the heaviest session in the last 60 trading days (the next-highest was 21,498 on July 13). Two things the disclosure does not state are worth being precise about: it does not say how the ₹1,250.0 Cr consideration is being funded (the loan-agreement section of the Annexure reads 'Not applicable'), and it describes the transaction as an assignment of trademarks and related IP — it does not spell out the commercial arrangements under which the brand's sales would flow to Novartis India. Both are inferences readers should wait on rather than assume.

The last ratio is the striking one. Novartis India's own revenue over the four quarters to June 2026 was ₹370.6 Cr (₹103.81 Cr + ₹90.55 Cr + ₹85.90 Cr + ₹90.33 Cr). The brand it has just bought the trademarks for recorded ₹228.6 Cr over the IQVIA MAT July 2026 period — equal to roughly 62% of the company's entire trailing revenue base. If Minipress sales were ultimately to run through Novartis India's accounts — which, again, the filing does not state — this would be a transformation of the P&L, not an addition to it. What the filing does establish is the price: ₹1,250.0 Cr against ₹97.8 Cr of trailing-twelve-month net profit for the whole company.

The new ownership has moved quickly on structure. On August 7, the board adopted a new set of Articles of Association, approved an Employee Stock Option Plan 2026, and approved the termination of a Distribution and Promotion Agreement dated February 11, 2022 — all subject to shareholder approval where required. On August 17, it adopted a new Memorandum of Association and approved a proposal to change the company's name, for which approval from the Central Registration Centre has been received, subject to shareholders at the AGM. That AGM — the 78th — is scheduled for September 24 via video conference. The Minipress purchase is the first balance-sheet-scale transaction of the new era, and its size suggests — this is inference, not a filed statement — that the listed company is being positioned as a platform for brand acquisitions rather than run as a static portfolio.

The buyers paid ₹1,376.89 Cr for 70.68% of the company in July. In September, the company itself committed ₹1,250 Cr — for one brand.

The tape's big move predates the deal: the stock is up from a 52-week adjusted low of ₹750 (January 21) to ₹1,658.95 — a gain of about 121% — with the steepest leg coming through July as the ownership transition played out, and the adjusted 52-week high of ₹1,777.5 printed on July 23, the day Q1 results landed. The block price computed from the promoter-stake disclosure, roughly ₹789 a share on July 29, sits far below where the market has since traded — though an off-market control transfer negotiated in February and the open-market price of September measure different things and are not directly comparable. From the September 7 close, the stock sits 6.7% below its 52-week high.

The operating business is small, profitable and improving: quarterly revenue has run between ₹84 Cr and ₹104 Cr for eight quarters, with Q1 FY27 the best of them on both revenue and margin. The company carries almost no interest cost in its P&L (₹0.06 Cr in Q1 FY27). That is precisely why the funding question matters — a ₹1,250.0 Cr outlay is more than three times the company's annual revenue and nearly thirteen times its trailing annual profit, and the filing is silent on whether it is met from cash, borrowings or otherwise. The FY26 annual report, filed September 2 ahead of the AGM, and the H1 FY27 results will be the first places the balance-sheet answer can appear.